



MICHIGAN STATE UNIVERSITY
BOARD OF TRUSTEES
Executive Action Summary

Audit, Risk, & Compliance-Attachment 1a

APPROVED
DECEMBER 13, 2024
BOARD OF TRUSTEES
MICHIGAN STATE UNIVERSITY

Committee Name: Audit, Risk & Compliance

Date: December 13, 2024

Agenda Item: Michigan State University (MSU) and Proton Bio, Inc.

Information

Discussion

Action

Resolution:

BE IT RESOLVED, that the Board of Trustees of Michigan State University hereby approves a sponsored research agreement with Proton Bio, Inc. consistent with the term sheet now presented to the Board of Trustees for inclusion in its minutes.

Recommendation:

The Trustee Committee on Audit, Risk, & Compliance recommends that the Board of Trustees authorize the agreement between Michigan State University and Proton Bio, Inc. in which Michigan State University faculty members, Dr. Charles Hong and Dr. Charles Williams, hold a financial interest.

Prior Action by BOT:

Not applicable.

Responsible Officers:

Douglas A. Gage, Vice President for Research and Innovation

Summary:

Michigan State University will carry out the following testing:

- MSU will provide pharmacokinetics (PK), blood brain barrier (BBB) permeability, cytochrome (CYP) phenotyping, and plasma protein binding services.

Background Information:

The attached term sheet summarizes the agreement between Michigan State University and Proton Bio, Inc.

Source of Funds:

The National Institutes of Health will provide \$138,380.05 to MSU for this project.

Resource Impact:

MSU faculty, Dr. Edmund Ellsworth will serve as the Principal investigator for the project. MSU's Life Sciences Building will be utilized for this project.

MICHIGAN STATE UNIVERSITY

SPONSORED RESEARCH AGREEMENT TERM SHEET

Party:	Proton Bio, Inc.
Project Description:	Targeting Proton-sensing GPR68 as a ferroptosis-based therapy for Glioblastoma
Term:	1/1/2025-12/31/2025
Financial Terms:	\$137,380.05 funded by the National Institutes of Health
Services Provided:	By MSU to company: MSU will provide PK, BBB permeability, CYP phenotyping, and plasma protein binding services. By company to MSU: None.
Use of University Facilities/Personnel:	Life Sciences Building. Dr. Edmund Ellsworth (Principal Investigator)
Organization Type and Domicile:	Limited Liability Company
Personnel Interest:	Dr. Charles Williams, MSU Assistant Professor in the Department of Medicine and Dr. Charles Hong, Chairperson in the Department of Medicine, holds a financial interest in this company.



Office of
**RESEARCH
AND INNOVATION**

Douglas A. Gage, Ph.D.
Vice President

Hannah Administration Bldg.
426 Auditorium Rd, Rm 249
East Lansing, MI 48824

517/355-0306
Fax: 517/432-1171

gage@msu.edu



MICHIGAN STATE UNIVERSITY
BOARD OF TRUSTEES
Executive Action Summary

Committee Name: Audit, Risk, & Compliance

Date: December 13, 2024

Agenda Item: Michigan State University (“MSU”) and Iaso Therapeutics, Inc.

Information

Discussion

Action

Resolution:

BE IT RESOLVED, that the Board of Trustees of Michigan State University hereby approves a sponsored research agreement with Iaso Therapeutics, Inc. consistent with the term sheet now presented to the Board of Trustees for inclusion in its minutes.

Recommendation:

The Trustee Committee on Audit, Risk, & Compliance recommends that the Board of Trustees authorize the agreement between Michigan State University (MSU) and Iaso Therapeutics, Inc. in which Michigan State University faculty member, Dr. Xuefei Huang, holds a financial interest.

Prior Action by BOT:

The Board previously approved sponsored research agreements with Iaso Therapeutics, Inc. on February 11, 2022, September 8, 2023, April 12, 2024, and September 6, 2024.

The Board previously approved licensing agreements with Iaso Therapeutics, Inc. on June 18, 2021, October 29, 2021, and September 9, 2022.

The Board previously approved an option agreement with Iaso Therapeutics, Inc. on September 10, 2021.

The Board previously approved service agreements with Iaso Therapeutics, Inc. on April 6, 2021 and June 18, 2021.

Responsible Officers:

Douglas A. Gage, Vice President for Research and Innovation

Summary:

Michigan State University will carry out the following testing:

- MSU will conduct experiments involving a vaccine construct consisting of trisaccharide carbohydrate antigen derived from Salmonella O-polysaccharide antigen conjugated to an mQ β carrier protein (mQ β -Trisaccharide) which will be investigated for immunological responses and disease challenge experiments.

Background Information:

The attached term sheet summarizes the agreement between Michigan State University and Iaso Therapeutics, Inc.

Source of Funds:

Iaso Therapeutics, Inc. will pay Michigan State University \$40,000 dollars. Payment shall be made to MSU upon receipt of an invoice.

Resource Impact:

The laboratory of MSU faculty member, Dr. Zhen Qiu in the Department of Biomedical Engineering, will conduct this project and has the requisite expertise and laboratory equipment. The MSU Medicinal Chemistry (CORE) Facility will also provide support.

MICHIGAN STATE UNIVERSITY

SPONSORED RESEARCH AGREEMENT TERM SHEET

Party:	Iaso Therapeutics, Inc.
Project Description:	Iaso Therapeutics, Inc. is developing next generation vaccines which utilize a proprietary genetically modified capsid protein, mutant Qb (mQb). MSU will conduct experiments involving a vaccine construct consisting of trisaccharide carbohydrate antigen derived from Salmonella O-polysaccharide antigen conjugated to an mQ β carrier protein (mQ β -Trisaccharide) which will be investigated for immunological responses and disease challenge experiments. The laboratory of Zhen Qiu in the Department of Biomedical has the capability to conduct this project and the requisite expertise and laboratory equipment. The MSU Medicinal Chemistry (CORE) Facility will also provide support.
Term:	December 15, 2024 to December 14, 2026
Financial Terms:	The total amount to be paid to the University by Iaso Therapeutics, Inc. will be \$40,000. Payment shall be made to the University by Iaso Therapeutics, Inc. upon the receipt of an invoice.
Services Provided:	By MSU to company: A detailed report summarizing the experimental procedures, results, conclusions, and recommendations for the next steps will be provided. By company to MSU: Iaso Therapeutics, Inc. will provide payment for the research activities as described in the above Financial Terms.
Use of University Facilities/Personnel	MSU faculty member Dr. Zhen Qiu is the MSU Principal Investigator for this project.
Organization Type and Domicile:	Michigan Corporation
Personnel Interest:	MSU employee, Dr. Xuefei Huang has an ownership interest in and is an officer of Iaso Therapeutics, Inc.



Office of
**RESEARCH
AND INNOVATION**

Douglas A. Gage, Ph.D.
Vice President

Hannah Administration Bldg.
426 Auditorium Rd, Rm 249
East Lansing, MI 48824

517/355-0306
Fax: 517/432-1171

gage@msu.edu